FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013984355> ?p ?o ?g. }

• W2013984355 endingPage "277" @default.
• W2013984355 startingPage "269" @default.
• W2013984355 abstract "Purpose To obtain reliable estimates of the relative efficacy and safety of low-molecular-weight heparins (LMWHs) and unfractionated heparin (UFH) in the treatment of patients with venous thromboembolism. Methods A literature search of randomized trials evaluating LMWH and UFH for the period from 1980 to 1994 was conducted to obtain data for a meta-analysis. Studies were classified as level 1 if they were double-blind or if there was blinded assessment of outcome measures, and level 2 if they did not provide assurance of blinded outcome assessment. Results In level 1 studies, the relative risk (RR) of recurrent venous thromboembolism during the first 15 days and over the entire period of anticoagulant therapy was 0.24 (95% confidence intervals [Cl] 0.06 to 0.80, P = 0.02) and 0.39 (95% Cl 0.30 to 0.80, P = 0.006), respectively, in favor of LMWH treatment. The RR for major bleeding was 0.42 (95% Cl 0.2 to 0.9, P = 0.01), in favor of LMWH. In level 2 studies, no significant differences in the rates of recurrent venous thromboembolism or major bleeding were observed. Pooling level 1 and level 2 studies, the RR for overall mortality and mortality in cancer patients was 0.51 (95% Cl 0.2 to 0.9, P = 0.01) and 0.33 (95% Cl 0.1 to 0.8, P = 0.01), respectively, in favor of LMWH. Conclusions LMWH are likely to be more effective than UFH in preventing recurrent venous thromboembolism, to produce less major bleeding, and to be associated with a lower mortality rate, particularly in the subgroup of patients with cancer. To obtain reliable estimates of the relative efficacy and safety of low-molecular-weight heparins (LMWHs) and unfractionated heparin (UFH) in the treatment of patients with venous thromboembolism. A literature search of randomized trials evaluating LMWH and UFH for the period from 1980 to 1994 was conducted to obtain data for a meta-analysis. Studies were classified as level 1 if they were double-blind or if there was blinded assessment of outcome measures, and level 2 if they did not provide assurance of blinded outcome assessment. In level 1 studies, the relative risk (RR) of recurrent venous thromboembolism during the first 15 days and over the entire period of anticoagulant therapy was 0.24 (95% confidence intervals [Cl] 0.06 to 0.80, P = 0.02) and 0.39 (95% Cl 0.30 to 0.80, P = 0.006), respectively, in favor of LMWH treatment. The RR for major bleeding was 0.42 (95% Cl 0.2 to 0.9, P = 0.01), in favor of LMWH. In level 2 studies, no significant differences in the rates of recurrent venous thromboembolism or major bleeding were observed. Pooling level 1 and level 2 studies, the RR for overall mortality and mortality in cancer patients was 0.51 (95% Cl 0.2 to 0.9, P = 0.01) and 0.33 (95% Cl 0.1 to 0.8, P = 0.01), respectively, in favor of LMWH. LMWH are likely to be more effective than UFH in preventing recurrent venous thromboembolism, to produce less major bleeding, and to be associated with a lower mortality rate, particularly in the subgroup of patients with cancer." @default.
• W2013984355 created "2016-06-24" @default.
• W2013984355 creator A5000914852 @default.
• W2013984355 creator A5043870217 @default.
• W2013984355 creator A5055785288 @default.
• W2013984355 creator A5071135543 @default.
• W2013984355 creator A5085841362 @default.
• W2013984355 date "1996-03-01" @default.
• W2013984355 modified "2023-10-18" @default.
• W2013984355 title "Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis" @default.
• W2013984355 cites W149105390 @default.
• W2013984355 cites W1560647893 @default.
• W2013984355 cites W1600823549 @default.
• W2013984355 cites W1968717961 @default.
• W2013984355 cites W1984597181 @default.
• W2013984355 cites W1992460911 @default.
• W2013984355 cites W1994898034 @default.
• W2013984355 cites W2004169137 @default.
• W2013984355 cites W2012850475 @default.
• W2013984355 cites W2017766892 @default.
• W2013984355 cites W2020578178 @default.
• W2013984355 cites W2028222320 @default.
• W2013984355 cites W2033724005 @default.
• W2013984355 cites W2034586141 @default.
• W2013984355 cites W2036907646 @default.
• W2013984355 cites W2037789405 @default.
• W2013984355 cites W2037985170 @default.
• W2013984355 cites W2039128844 @default.
• W2013984355 cites W2040655619 @default.
• W2013984355 cites W2045716011 @default.
• W2013984355 cites W2054098499 @default.
• W2013984355 cites W2058426392 @default.
• W2013984355 cites W2067550511 @default.
• W2013984355 cites W2072541939 @default.
• W2013984355 cites W2073325230 @default.
• W2013984355 cites W2086808806 @default.
• W2013984355 cites W2093491931 @default.
• W2013984355 cites W2105494532 @default.
• W2013984355 cites W2112339576 @default.
• W2013984355 cites W2112799238 @default.
• W2013984355 cites W2118015645 @default.
• W2013984355 cites W2140325175 @default.
• W2013984355 cites W2314539657 @default.
• W2013984355 cites W2338618131 @default.
• W2013984355 cites W2339052478 @default.
• W2013984355 cites W2512281683 @default.
• W2013984355 cites W338824617 @default.
• W2013984355 cites W4239720284 @default.
• W2013984355 cites W4248750125 @default.
• W2013984355 cites W4323283745 @default.
• W2013984355 cites W57097576 @default.
• W2013984355 cites W84205322 @default.
• W2013984355 doi "https://doi.org/10.1016/s0002-9343(97)89484-3" @default.
• W2013984355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8629671" @default.
• W2013984355 hasPublicationYear "1996" @default.
• W2013984355 type Work @default.
• W2013984355 sameAs 2013984355 @default.
• W2013984355 citedByCount "347" @default.
• W2013984355 countsByYear W20139843552012 @default.
• W2013984355 countsByYear W20139843552013 @default.
• W2013984355 countsByYear W20139843552014 @default.
• W2013984355 countsByYear W20139843552015 @default.
• W2013984355 countsByYear W20139843552016 @default.
• W2013984355 countsByYear W20139843552017 @default.
• W2013984355 countsByYear W20139843552018 @default.
• W2013984355 countsByYear W20139843552020 @default.
• W2013984355 countsByYear W20139843552021 @default.
• W2013984355 countsByYear W20139843552023 @default.
• W2013984355 crossrefType "journal-article" @default.
• W2013984355 hasAuthorship W2013984355A5000914852 @default.
• W2013984355 hasAuthorship W2013984355A5043870217 @default.
• W2013984355 hasAuthorship W2013984355A5055785288 @default.
• W2013984355 hasAuthorship W2013984355A5071135543 @default.
• W2013984355 hasAuthorship W2013984355A5085841362 @default.
• W2013984355 hasConcept C126322002 @default.
• W2013984355 hasConcept C141071460 @default.
• W2013984355 hasConcept C168563851 @default.
• W2013984355 hasConcept C2776884760 @default.
• W2013984355 hasConcept C2777557582 @default.
• W2013984355 hasConcept C2780868729 @default.
• W2013984355 hasConcept C2991741193 @default.
• W2013984355 hasConcept C44249647 @default.
• W2013984355 hasConcept C71924100 @default.
• W2013984355 hasConcept C82789193 @default.
• W2013984355 hasConcept C95190672 @default.
• W2013984355 hasConceptScore W2013984355C126322002 @default.
• W2013984355 hasConceptScore W2013984355C141071460 @default.
• W2013984355 hasConceptScore W2013984355C168563851 @default.
• W2013984355 hasConceptScore W2013984355C2776884760 @default.
• W2013984355 hasConceptScore W2013984355C2777557582 @default.
• W2013984355 hasConceptScore W2013984355C2780868729 @default.
• W2013984355 hasConceptScore W2013984355C2991741193 @default.
• W2013984355 hasConceptScore W2013984355C44249647 @default.
• W2013984355 hasConceptScore W2013984355C71924100 @default.
• W2013984355 hasConceptScore W2013984355C82789193 @default.
• W2013984355 hasConceptScore W2013984355C95190672 @default.
• W2013984355 hasIssue "3" @default.
• W2013984355 hasLocation W20139843551 @default.

• next